Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAT | P00750 | 2/20 | 0.44 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.34 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.32 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.32 |
| ▸ | CDK2 | P24941 | 1/20 | 0.32 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.32 |
| ▸ | GCK | P35557 | 2/20 | 0.32 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.31 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13297993 | 0.76 | PARP1 (0.49) | PLATPARP1NPY5R | |
| SCHEMBL1069309 | 0.74 | PLAT (0.51) | PLATPARP1 | |
| SCHEMBL3300154 | 0.72 | PARP1 (0.46) | PLATPARP1 | |
| SCHEMBL20450053 | 0.66 | PLAT (0.46) | PLATPARP1CYP17A1 | |
| SCHEMBL5055420 | 0.65 | PLAT (0.62) | PLATPARP1 | |
| SCHEMBL13298076 | 0.65 | LMNA (0.33) | CHEK1CCNA2CDK2CCNA1 | |
| SCHEMBL29785683 | 0.62 | CHEK1 (0.39) | P2RX7CHEK1NISCH | |
| SCHEMBL17738448 | 0.61 | PLAT (1.00) | PLAT | |
| SCHEMBL4053090 | 0.61 | PARP1 (0.88) | PARP1 | |
| SCHEMBL14250161 | 0.61 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7741318-B2 | Pyrazolo [1,5-A]pyrimidine adenosine A2a receptor antagonists | SCHERING CORPORATION (US) | 2010-06-22 | — | — | US | disclosed |
| US-7741318-B2 | Pyrazolo [1,5-A]pyrimidine adenosine A2a receptor antagonists | SCHERING CORPORATION (US) | 2010-06-22 | — | — | US | disclosed |
| US-7741318-B2 | Pyrazolo [1,5-A]pyrimidine adenosine A2a receptor antagonists | SCHERING CORPORATION (US) | 2010-06-22 | — | — | US | disclosed |
| EP-1836205-B1 | PYRAZOLO[1,5-A]PYRIMIDINE ADENOSINE A2a RECEPTOR ANTAGONISTS | SCHERING CORP (US) | 2009-06-10 | — | — | EP | disclosed |
| EP-1836205-B1 | PYRAZOLO[1,5-A]PYRIMIDINE ADENOSINE A2a RECEPTOR ANTAGONISTS | SCHERING CORP (US) | 2009-06-10 | — | — | EP | disclosed |
| EP-1836205-A2 | PYRAZOLO[1,5-A]PYRIMIDINE ADENOSINE A2a RECEPTOR ANTAGONISTS | SCHERING CORPORATION (US) | 2007-09-26 | — | — | EP | disclosed |
| WO-2006068954-A2 | PYRAZOLO[1,5-A]PYRIMIDINE ADENOSINE A2a RECEPTOR ANTAGONISTS | SCHERING CORPORATION (US) | 2006-06-29 | — | — | WO | disclosed |
| US-20060135526-A1 | Pyrazolo [1,5-A] pyrimidine adenosine A2a receptor antagonists | MERCK SHARP & DOHME LLC | 2006-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135526-A1 | Pyrazolo [1,5-A] pyrimidine adenosine A2a receptor antagonists | ADORA2A, ADORA3, ADORA2B | PLAT 1512/4885PARP1 1258/4885NPY5R 167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.